Pieris Pharmaceuticals

CEO Stephen S. Yoder
USA | Funding: $160M (+)
Website: https://www.pieris.com
Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, inhaled Anticalin proteins to treat respiratory diseases, such as uncontrolled asthma, and a half-life-optimized Anticalin protein to treat anemia.
Website: https://www.pieris.com
Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, inhaled Anticalin proteins to treat respiratory diseases, such as uncontrolled asthma, and a half-life-optimized Anticalin protein to treat anemia.

